Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1%

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 93,141 shares, a decrease of 64.1% from the July 15th total of 259,720 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average trading volume of 88,009 shares, the short-interest ratio is currently 1.1 days.

Indaptus Therapeutics Trading Up 1.8%

INDP traded up $0.02 during trading on Friday, hitting $1.08. 29,705 shares of the company’s stock were exchanged, compared to its average volume of 451,192. Indaptus Therapeutics has a 1 year low of $0.92 and a 1 year high of $8.57. The firm has a market cap of $122.19 million, a P/E ratio of -0.07 and a beta of 1.18. The stock has a 50 day moving average price of $2.57 and a 200 day moving average price of $2.22.

Indaptus Therapeutics (NASDAQ:INDP) last posted its earnings results on Thursday, August 13th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.57) by $1.55.

Institutional Investors Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics as of its most recent SEC filing. 7.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on INDP. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Indaptus Therapeutics presently has an average rating of “Sell”.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.